Reyon Pharmaceutical (Representative Directors: Jung SoonOck, Yoo Yonghwan) announced that the company would participate in Bioplus-Interpex Korea 2022 (BIX 2022), one of the largest general biotechnology conventions in Korea, held at COEX, Seoul, for three days from the 3rd to expand its partnership.
(Reyon Pharmaceutical in the BIX 2022 Exhibition Hall)
'Bioplus-Interpex Korea,' celebrating its 8th anniversary this year, is co-hosted by the Korea Bio Association and Lead Exhibitions Korea. This convention shares the value chain of domestic and foreign bio/pharmaceutical industries while preparing a foothold for overseas expansion through global business networking.
At BIX 2022, Reyon Pharmaceutical plans to showcase the cGMP production facilities and capacity of its Chungju plant, expand joint development partnerships, and discuss CDMO/CMO business.
The biopharmaceutical plant completed in Chungju by Reyon Pharmaceutical responds to multiple modalities such as plasmid DNA (pDNA), mRNA, viral vector, and phage. This state-of-the-art production facility produces biopharmaceuticals in one-stop from bulk (drug substances, DSs) to finished product (drug products, DPs).
Through multi-use and single-use fermenters of various sizes, the biopharmaceutical drug substance (DS) production line simultaneously produces multiple materials based on microbial fermentation (e.g., pDNA) with small-scale (e.g., clinical samples) and large-scale commercial production capabilities.
Regarding finished products (DP), it has the excellent production capacity to mass-produce liquid and freeze-dried injections of microorganism-based biopharmaceuticals and state-of-the-art antibody drugs through single-use production facilities that fundamentally block cross-contamination.
Kim Young-min, Director of the Bio Business Division at REYON Pharmaceutical, said, "The Chungju Plant can shorten the clinical development period for partners by establishing a stable, phase-specific supply chain of various pipelines." He added, "Reyon Pharmaceutical is in the process of joint development of several new drug pipelines with various partners based on its excellent production infrastructure. The company declares the full-scale debut of its Chungju plant through BIX 2022 while pursuing additional full-fledged partnerships with many companies."
Meanwhile, Reyon Pharmaceutical is also accelerating its CMO/CDMO business based on the production capacity of its Chungju plant. In addition, it is continuing discussions on bio-CMO businesses with various companies, including acquiring orders to supply four types of pDNA in April this year.
In addition, Chungju Chemical Plant, located on the same site, is also speeding up GMP certification to acquire production capacity, and based on its large-scale production capacity for chemical drugs, it is actively conducting CMO businesses with many traditional pharmaceutical companies.
